MAPC generation of muscle

• US 8,252,280 B1
• Filed: 05/11/2011
• Issued: 08/28/2012
• Est. Priority Date: 08/05/1999
• Status: Expired due to Term

• Current Assignee: Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Verfaillie, Catherine M., Gallegos, Robert, Jerosch-Herold, Michael
• Primary Examiner(s): Kim, Taeyoon
• Application Number:
  US13/105,372
• Time in Patent Office: 475 Days
• Field of Search: 424/93.7, 424/577, 435/366, 435/325
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/14 Blood; Artificial blood perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 35/34 Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes vascular smooth muscle A61K35/44
• CPC Class Codes: A61K 35/36 Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells islets of Langerhans A61K35/39
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61K 38/19 Cytokines; Lymphokines; Interferons

Abstract

The present invention relates to methods of increasing function and/or mass in damaged striated muscle tissue of interest (e.g., cardiac or muscle tissue) by providing of a population of multipotent adult progenitor cells (“MAPCs”), which effectively generate new striated muscle over time.

Claims

1. A method of providing striated muscle to a subject in need thereof, the method comprising administering to the subject, in amounts effective to provide new striated muscle, isolated human non-embryonic non-germ cells that do not express CD45 or glyA and express oct3/4, telomerase, rex-1, and rox-1, and are not transformed, wherein the subject has existing striated muscle, and wherein the isolated non-embryonic non-germ cells are expanded in cell culture medium prior to administration to the subject.

4. The method of claim 1, wherein existing striated muscle in the subject is damaged by disease.

5. The method of claim 4, wherein the disease is selected from the group consisting of congestive heart failure, coronary artery disease, myocardial infarction, myocardial ischemia, atherosclerosis, cardiomyopathy, idiopathic cardiomyopathy, cardiac arrhythmias, muscular dystrophy, muscle mass abnormalities, muscle degeneration, infective myocarditis, drug- and toxin-induced muscle abnormalities, hypersensitivity myocarditis, autoimmune endocarditis, and congenital heart disease.

6. The method of claim 1 or 2, wherein the new striated muscle is cardiac muscle.

7. The method of claim 1 or 2, wherein the new striated muscle is skeletal muscle.

8. The method of claim 1 or 3, wherein the isolated non-embryonic non-germ cells are administered using techniques selected from the group consisting of surgical intramyocardial injection, transendocardial injection, intracoronary injection, transvascular injection, intramuscular injection, intravenous injection and cardiac catheter administration.

11. The method of claim 1 or 3, wherein the subject is human.

12. The method of any one of claims 1-3, wherein the non-embryonic non-germ cells are isolated from bone marrow, muscle, brain, spinal cord, blood or skin.

13. The method of claim 1 or 3, wherein the non-embryonic non-germ cells are administered in the presence of cytokines, growth factors or a combination thereof.

14. The method of claim 1 or 3, wherein the administered non-embryonic non-germ cells are autologous cells.

15. The method of claim 1 or 3, wherein the administered non-embryonic non-germ cells are allogeneic cells.

16. The method of any of claims 1-3 wherein said isolated non-embryonic non-germ cells can differentiate into at least cell type of at least two of the mesodermal, endodermal, and ectodermal embryonic lineages.

17. The method of claim 16 wherein said non-embryonic non-germ cells can differentiate into at least one cell type of each of the endodermal, ectodermal and mesodermal lineages.

2. A method of increasing striated muscle mass, the method comprising contacting, in amounts effective to generate new striated muscle, isolated human non-embryonic non-germ cells that do not express CD45 or glyA and express oct3/4, telomerase, rex-1, and rox-1, and are not transformed, with existing striated muscle, and wherein the isolated non-embryonic non-germ cells are expanded in cell culture medium prior to administration to the subject.

3. A method for producing striated muscle cells in a subject, the method comprising administering to the subject, in amounts effective to produce striated muscle cells, isolated human non-embryonic non-germ cells that do not express CD45 or glyA and express oct3/4, telomerase, rex-1, and rox-1, and are not transformed, and wherein the isolated non-embryonic non-germ cells are expanded in cell culture medium prior to administration to the subject.

9. The method of claim 3, wherein the striated muscle cells are cardiac muscle cells.

10. The method of claim 3, wherein the striated muscle cells are skeletal muscle cells.